Xu Jing, Wang Hong-Wei, Li Xiao-Hong, Zhu Lei, Zhang Li, Zhang Fan, Tan Yan-Hong, Yang Tao
Institute of Hematology, The Second Hospital, Shanxi Medical University, Taiyuan 030001, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Jun;15(3):603-6.
The Wilms' tumor gene (WT1) is a transcription factor involved in tumorigenesis, especially in leukemogenesis. However, the role of WT1 expression in nonmalignant hematopoietic cells remains unclear. Furthermore, due to alternative splicing at two sites: 17 amino acid residues of exon 5 (+17AA) and 3 amino acid residues (+KTS) between exons 9 and 10, WT1 gene has four main isoforms (17AA+/KTS+, 17AA+/KTS-, 17AA-/KTS+, 17AA-/KTS-, abbreviation: +/+, +/-, -/+, -/-). The isoforms probably existed in hematopoietic cells, which make the research more complex. The aim of study was to elucidate the expression and its isoforms of WT1 gene in different cell subsets of healthy bone marrow donors. The fluorescence RT-PCR detection system was established to measure the expressions of full-length WT1, WT1 (+17AA) and WT1 (+KTS) in CD34(+)CD38(-) (stem cell), CD34(+)CD38(+) (progenitor cell), CD15(+)CD11b(+) (granulocyte), CD33(+)CD14(+) (monocyte), CD20(+)CD5(-) (B-lymphocyte) and CD20(-)CD5(+) (T-lymphocyte) subsets from 18 normal human bone marrow samples. The results showed that WT1 expressed in CD34(+)CD38(-), CD34(+)CD38(+), CD15(+)CD11b(+) and CD33(+)CD14(+), but not in CD20(+)CD5(-) and CD20(-)CD5(+) subsets. The highest expression was in CD34(+)CD38(-), but decreased gradually in CD15(+)CD11b(+) and CD33(+)CD14(+) subsets. WT1 (+17AA), WT1 (+KTS) and WT1 (+/+) isoforms were predominant in CD34(+)CD38(-) and CD34(+)CD38(+) primitive subsets, while in CD15(+)CD11b(+) and CD33(+)CD14(+) the dominant isoforms were WT1 (-17AA), WT1 (-KTS) and WT1 (-/-). It is concluded that the expression of WT1 in normal bone marrow decreases gradually with cell differentiation. Hematopoietic cells may adjust the ratios of WT1 isoforms to inhibit or promote cell differentiation.
威尔姆斯瘤基因(WT1)是一种参与肿瘤发生,尤其是白血病发生的转录因子。然而,WT1在非恶性造血细胞中的表达作用仍不清楚。此外,由于在两个位点存在可变剪接:外显子5的17个氨基酸残基(+17AA)以及外显子9和10之间的3个氨基酸残基(+KTS),WT1基因有四种主要的异构体(17AA+/KTS+、17AA+/KTS-、17AA-/KTS+、17AA-/KTS-,缩写:+/+、+/-、-/+、-/-)。这些异构体可能存在于造血细胞中,这使得研究更加复杂。本研究的目的是阐明WT1基因在健康骨髓供体不同细胞亚群中的表达及其异构体情况。建立了荧光RT-PCR检测系统,以检测18份正常人骨髓样本中CD34(+)CD38(-)(干细胞)、CD34(+)CD38(+)(祖细胞)、CD15(+)CD11b(+)(粒细胞)、CD33(+)CD14(+)(单核细胞)、CD20(+)CD5(-)(B淋巴细胞)和CD20(-)CD5(+)(T淋巴细胞)亚群中全长WT1、WT1(+17AA)和WT1(+KTS)的表达。结果显示,WT1在CD34(+)CD38(-)、CD34(+)CD38(+)、CD15(+)CD11b(+)和CD33(+)CD14(+)中表达,但在CD20(+)CD5(-)和CD20(-)CD5(+)亚群中不表达。最高表达在CD34(+)CD38(-)中,但在CD15(+)CD11b(+)和CD33(+)CD14(+)亚群中逐渐降低。WT1(+17AA)、WT1(+KTS)和WT1(+/+)异构体在CD34(+)CD38(-)和CD34(+)CD38(+)原始亚群中占主导,而在CD15(+)CD11b(+)和CD33(+)CD14(+)中占主导的异构体是WT1(-17AA)、WT1(-KTS)和WT1(-/-)。结论是,WT1在正常骨髓中的表达随细胞分化逐渐降低。造血细胞可能通过调节WT1异构体的比例来抑制或促进细胞分化。